Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
复制标题
DOI：
10.5858/arpa.2018-0902-sa
复制
发表时间：
2018-11-01
影响因子：
4.6
通讯作者：
Dowsett, Mitchell
中科院分区：
文献类型：
--
作者：
Wolff, Antonio C.;Hammond, M. Elizabeth Hale;Dowsett, Mitchell
目的。-更新美国临床肿瘤学会（ASCO）/美国病理学家学会（CAP）人类表皮生长因子受体2（HER 2）检测在乳腺癌指南中的关键建议。基于信号方法，一个专家小组审查了已发表的文献和研究调查结果，观察到的不太常见的原位杂交（ISH）模式的频率，以更新说明。其中包括2015年通过信函处理的两项建议。首先，免疫组织化学（IHC）2+被定义为浸润性乳腺癌，在>10%的肿瘤细胞中观察到弱至中度的完全膜染色。第二，如果在一个核心针活检标本的原发性乳腺癌的初始HER 2测试结果是阴性的，一个新的HER 2测试可以（不是“必须”）被责令切除标本基于特定的临床标准。更新了乳腺癌的HER 2检测算法，以解决使用双探针ISH检测时观察到的不太常见的临床情况（约5%的病例）的建议检查。这些情况被描述为ISH组2（HER 2/染色体计数探针17 [CEP 17]比率>= 2.0;平均HER 2拷贝数，
Purpose.-To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline.Methods.-Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations.Recommendations.-Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must'') be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 (HER2/chromosome enumeration probe 17 [CEP17] ratio >= 2.0; average HER2 copy number,